Radiation and the heart: systematic review of dosimetry and cardiac endpoints

References

• Jaffray DA, Gospodarowicz MK. Radiation therapy for cancer. In: Gelband H, Jha P, Sankaranarayanan R, et al. editors. Cancer: disease control priorities. Third. Vol. 3. Washington (DC): 2015.
   Google Scholar
• Lancellotti P, Nkomo VT, Badano LP, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European association of cardiovascular imaging and the American society of echocardiography. Eur Heart J Cardiovasc Imaging. 2013 Aug;14(8):721–740. PubMed PMID: 23847385; eng.
   PubMed Web of Science ®Google Scholar
• van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer [Multicenter StudyRandomized Controlled Trial Research Support, Non-U.S. Gov’t]. N Engl J Med. 2012 May 31;366(22):2074–2084. PubMed PMID: 22646630; eng.
   PubMed Web of Science ®Google Scholar
• Lin SH, Wang L, Myles B, et al. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer [Comparative Study Research Support, N.I.H., Extramural]. Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1078–1085. PubMed PMID: 22867894; PubMed Central PMCID: PMC3923623. eng.
   PubMed Web of Science ®Google Scholar
• Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study [Clinical Trial, Phase III Comparative Study Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Lancet Oncol. 2015 Feb;16(2):187–199. PubMed PMID: 25601342; PubMed Central PMCID: PMC4419359. eng.
   PubMed Web of Science ®Google Scholar
• Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: A secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial [Article]. J Clin Oncol. 2017;35(1):56–62.
   PubMed Web of Science ®Google Scholar
• Taylor C, Correa C, Duane FK, et al. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J clin oncol. 2017 May 20;35(15):1641–1649. PubMed PMID: 28319436; PubMed Central PMCID: PMCPMC5548226. eng.
   PubMed Web of Science ®Google Scholar
• Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J clin oncol. 2010 Mar 10;28(8):1308–1315. PubMed PMID: 20142603; eng.
   PubMed Web of Science ®Google Scholar
• Johnson MD, Sura K, Mangona VS, et al. Matched-pair analysis of high dose versus standard dose definitive chemoradiation for locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2017 Mar;18(2):149–155. PubMed PMID: WOS:000397933900013.
   PubMed Web of Science ®Google Scholar
• Speirs CK, DeWees TA, Rehman S, et al. Heart dose is an independent dosimetric predictor of overall survival in locally advanced non-small cell lung cancer. J thoracic oncol. 2017 Feb;12(2):293–301. PubMed PMID: 27743888; eng.
   PubMed Web of Science ®Google Scholar
• Schytte T, Hansen O, Stolberg-Rohr T, et al. Cardiac toxicity and radiation dose to the heart in definitive treated non-small cell lung cancer [Evaluation Studies Letter]. Acta Oncol. 2010 Oct;49(7):1058–1060. PubMed PMID: 20831496; eng.
   PubMed Web of Science ®Google Scholar
• McWilliam A, Kennedy J, Hodgson C, et al. Radiation dose to heart base linked with poorer survival in lung cancer patients [Article]. Eur J Cancer. 2017;85:106–113.
   PubMed Web of Science ®Google Scholar
• Stam B, Peulen H, Guckenberger M, et al. Dose to heart substructures is associated with non-cancer death after SBRT in stage I–II NSCLC patients [Article]. Radiother Oncol. 2017;123(3):370–375.
   PubMed Web of Science ®Google Scholar
• Tembhekar AR, Wright CL, Daly ME, et al. Survival after stereotactic body radiotherapy for early-stage non–small-cell lung cancer [Conference Paper]. Clin Lung Cancer. 2017;18(3):293–298.
   PubMed Web of Science ®Google Scholar
• Sio TT, Liang JJ, Chang K, et al. Outcomes after curative thoracic radiotherapy in patients with coronary artery disease and existing cardiac stents [Article]. Am J Clin Oncology: Cancer Clin Trials. 2016;39(6):549–555.
   PubMed Web of Science ®Google Scholar
• Sio TT, Liang JJ, Chang K, et al. Dosimetric correlate of cardiac-specific survival among patients undergoing coronary artery stenting after thoracic radiotherapy for cancer [Conference Paper]. Am J Clin Oncology: Cancer Clin Trials. 2017;40(2):133–139.
   PubMed Web of Science ®Google Scholar
• Cutter DJ, Schaapveld M, Darby SC, et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma [Article]. J Natl Cancer Inst. 2015;107:4.
   Google Scholar
• Cella L, Liuzzi R, Conson M, et al. Multivariate normal tissue complication probability modeling of heart valve dysfunction in Hodgkin lymphoma survivors [Research Support, Non-U.S. Gov’t]. Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):304–310. PubMed PMID: 23886419; eng.
   PubMed Web of Science ®Google Scholar
• Cella L, Palma G, Deasy JO, et al. Complication probability models for radiation-induced heart valvular dysfunction: do heart-lung interactions play a role? [Article]. PloS one. 2014;9:10.
   Web of Science ®Google Scholar
• Cella L, Oh JH, Deasy JO, et al. Predicting radiation-induced valvular heart damage [Article]. Acta Oncol. 2015;54(10):1796–1804.
   PubMed Web of Science ®Google Scholar
• Cella L, Liuzzi R, Conson M, et al. Dosimetric predictors of asymptomatic heart valvular dysfunction following mediastinal irradiation for Hodgkin’s lymphoma [Article]. Radiother Oncol. 2011;101(2):316–321.
   PubMed Web of Science ®Google Scholar
• Schellong G, Riepenhausen M, Bruch C, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies [Article]. Pediatr Blood Cancer. 2010;55(6):1145–1152.
   PubMed Web of Science ®Google Scholar
• Bhakta N, Liu Q, Yeo F, et al. Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin’s lymphoma: an analysis from the St Jude lifetime cohort study [Article]. Lancet Oncol. 2016;17(9):1325–1334.
   PubMed Web of Science ®Google Scholar
• Mulrooney DA, Armstrong GT, Huang S, et al. Cardiac outcomes in adult survivors of childhood cancer exposed to cardiotoxic therapy [Article]. Ann Intern Med. 2016;164(2):93–101.
   PubMed Web of Science ®Google Scholar
• Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the childhood cancer survivor study cohort [Article]. BMJ. 2009;339(7736):34.
   Google Scholar
• Van Der Pal HJ, Van Dalen EC, Van Delden E, et al. High risk of symptomatic cardiac events in childhood cancer survivors [Article]. J Clin Oncol. 2012;30(13):1429–1437.
   PubMed Web of Science ®Google Scholar
• Haddy N, Diallo S, El-Fayech C, et al. Cardiac diseases following childhood cancer treatment: cohort study [Article]. Circulation. 2016;133(1):31–38.
   PubMed Web of Science ®Google Scholar
• Armstrong GT, Joshi VM, Ness KK, et al. Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude lifetime cohort study [Article]. J Am Coll Cardiol. 2015;65(23):2511–2522.
   PubMed Web of Science ®Google Scholar
• Rademaker J, Schoder H, Ariaratnam NS, et al. Coronary artery disease after radiation therapy for Hodgkin’s lymphoma: coronary CT angiography findings and calcium scores in nine asymptomatic patients. Am J roentgenol. 2008 Jul;191(1):32–37. PubMed PMID: 18562721; eng.
   PubMed Web of Science ®Google Scholar
• Küpeli S, Hazirolan T, Varan A, et al. Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin’s lymphoma [Article]. J Clin Oncol. 2010;28(6):1025–1030.
   PubMed Web of Science ®Google Scholar
• de Ville de Goyet M, Brichard B, Robert A, et al. Prospective cardiac MRI for the analysis of biventricular function in children undergoing cancer treatments [Article]. Pediatr Blood Cancer. 2015;62(5):867–874.
   PubMed Web of Science ®Google Scholar
• MacHann W, Beer M, Breunig M, et al. Cardiac magnetic resonance imaging findings in 20-year survivors of mediastinal radiotherapy for Hodgkin’s disease [Article]. Int J Radiat Oncol Biol Phys. 2011;79(4):1117–1123.
   PubMed Web of Science ®Google Scholar
• Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials [Research Support, Non-U.S. Gov’t Review]. Lancet. 2005 Dec 17;366(9503):2087–2106. PubMed PMID: 16360786; eng.
   PubMed Web of Science ®Google Scholar
• McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials [Meta-Analysis Research Support, Non-U.S. Gov’t]. Lancet. 2014 Jun 21;383(9935):2127–2135. PubMed PMID: 24656685; PubMed Central PMCID: PMC5015598. eng.
   PubMed Web of Science ®Google Scholar
• Erven K, Florian A, Slagmolen P, et al. Subclinical cardiotoxicity detected by strain rate imaging up to 14 months after breast radiation therapy [Article]. Int J Radiat Oncol Biol Phys. 2013;85(5):1172–1178.
   PubMed Web of Science ®Google Scholar
• Skyttä T, Tuohinen S, Boman E, et al. Troponin T-release associates with cardiac radiation doses during adjuvant left-sided breast cancer radiotherapy [Article]. Radiat Oncol. 2015;10:1.
   PubMed Web of Science ®Google Scholar
• Derrico MP, Petruzzelli MF, Gianicolo EAL, et al. Kinetics of B-type natriuretic peptide plasma levels in patients with left-sided breast cancer treated with radiation therapy: results after one-year follow-up [Article]. Int J Radiat Biol. 2015;91(10):804–809.
   PubMed Web of Science ®Google Scholar
• Correa CR, Das IJ, Litt HI, et al. Association between tangential beam treatment parameters and cardiac abnormalities after definitive radiation treatment for left-sided breast cancer [Article]. Int J Radiat Oncol Biol Phys. 2008;72(2):508–516.
   PubMed Web of Science ®Google Scholar
• Cao L, Cai G, Chang C, et al. Diastolic dysfunction occurs early in HER2-positive breast cancer patients treated concurrently with radiation therapy and trastuzumab [Article]. Oncologist. 2015;20(6):605–614.
   PubMed Web of Science ®Google Scholar
• Bian SX, Korah MP, Whitaker TR, et al. No acute changes in LVEF observed with concurrent trastuzumab and breast radiation with low heart doses [Article]. Clin Breast Cancer. 2017;17(7):510–515.
   PubMed Web of Science ®Google Scholar
• Tjessem KH, Bosse G, Fosså K, et al. Coronary calcium score in 12-year breast cancer survivors after adjuvant radiotherapy with low to moderate heart exposure - Relationship to cardiac radiation dose and cardiovascular risk factors [Article]. Radiother Oncol. 2015;114(3):328–334.
   PubMed Web of Science ®Google Scholar
• Cao L, Hu WG, Kirova YM, et al. Potential impact of cardiac dose-volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy [Article]. Cancer/Radiotherapie. 2014;18(2):119–124.
   Google Scholar
• Saiki H, Petersen IA, Scott CG, et al. Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer [Article]. Circulation. 2017;135(15):1388–1396.
   PubMed Web of Science ®Google Scholar
• Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer [Research Support, Non-U.S. Gov’t]. N Engl J Med. 2013 Mar 14;368(11):987–998. PubMed PMID: 23484825; eng.
   PubMed Web of Science ®Google Scholar
• Van Den Bogaard VAB, Ta BDP, Van Der Schaaf A, et al. Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures [Article]. J Clin Oncol. 2017;35(11):1171–1178.
   PubMed Web of Science ®Google Scholar
• Gayed IW, Liu HH, Wei X, et al. Patterns of cardiac perfusion abnormalities after chemoradiotherapy in patients with lung cancer. J thoracic oncol. 2009 Feb;4(2):179–184. PubMed PMID: 19179893; eng.
   PubMed Web of Science ®Google Scholar
• Lee CB, Stinchcombe TE, Moore DT, et al. Late complications of high-dose (≥66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer [Article]. J Thorac Oncol. 2009;4(1):74–79.
   PubMed Web of Science ®Google Scholar
• Dess RT, Sun Y, Matuszak MM, et al. Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer [Article]. J Clin Oncol. 2017;35(13):1395–1402.
   PubMed Web of Science ®Google Scholar
• Wang K, Eblan MJ, Deal AM, et al. Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy [Article]. J Clin Oncol. 2017;35(13):1387–1394.
   PubMed Web of Science ®Google Scholar
• Wang K, Pearlstein KA, Patchett ND, et al. Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer [Article]. Radiother Oncol. 2017;125(2):293–300.
   PubMed Web of Science ®Google Scholar
• Ning MS, Tang L, Gomez DR, et al. Incidence and predictors of pericardial effusion after chemoradiation therapy for locally advanced non-small cell lung cancer [Article]. Int J Radiat Oncol Biol Phys. 2017;99(1):70–79.
   PubMed Web of Science ®Google Scholar
• Kamakura S, Shimizu W, Matsuo K, et al. Localization of optimal ablation site of idiopathic ventricular tachycardia from right and left ventricular outflow tract by body surface ECG [Clinical Trial]. Circulation. 1998 Oct 13;98(15):1525–1533. PubMed PMID: 9769306; eng.
   PubMed Web of Science ®Google Scholar
• Stahl M, Walz MK, Riera-Knorrenschild J, et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial [Clinical Trial, Phase III Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. Eur J Cancer. 2017 Aug;81:183–190. PubMed PMID: 28628843; eng.
   PubMed Web of Science ®Google Scholar
• Xi M, Xu C, Liao Z, et al. Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity modulated radiation therapy for esophageal cancer: a retrospective, single-institutional analysis. Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):667–676. PubMed PMID: 29280461.
   PubMed Web of Science ®Google Scholar
• Konski A, Li T, Christensen M, et al. Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer [Article]. Radiother Oncol. 2012;104(1):72–77.
   PubMed Web of Science ®Google Scholar
• Tait LM, Meyer JE, McSpadden E, et al. Women at increased risk for cardiac toxicity following chemoradiation therapy for esophageal carcinoma [Article]. Pract Radiat Oncol. 2013;3(4):e149–e155.
   PubMedGoogle Scholar
• Ogino I, Watanabe S, Iwahashi N, et al. Symptomatic radiation-induced cardiac disease in long-term survivors of esophageal cancer [Article]. Strahlentherapie und Onkologie. 2016;192(6):359–367.
   PubMed Web of Science ®Google Scholar
• Yeneneh BT, Allen S, Panse P, et al. Constrictive pericarditis 5 months after radiation therapy in a 62-year-old woman with esophageal cancer. Tex Heart Inst J. 2017 Dec;44(6):411–415. PubMed PMID: 29276442; PubMed Central PMCID: PMC5737154. eng.
   PubMed Web of Science ®Google Scholar
• Fukada J, Shigematsu N, Takeuchi H, et al. Symptomatic pericardial effusion after chemoradiation therapy in esophageal cancer patients [Article]. Int J Radiat Oncol Biol Phys. 2013;87(3):487–493.
   PubMed Web of Science ®Google Scholar
• Tamari K, Isohashi F, Akino Y, et al. Risk factors for pericardial effusion in patients with stage i esophageal cancer treated with chemoradiotherapy [Article]. Anticancer Res. 2014;34(12):7389–7393.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Fujiwara Y, Nomura M, et al. Predictive factors for pericardial effusion identified by heart dose-volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapy [Article]. Br J Radiol. 2015;88:1046.
   Web of Science ®Google Scholar
• Ogino I, Watanabe S, Sakamaki K, et al. Dosimetric predictors of radiation-induced pericardial effusion in esophageal cancer [Article]. Strahlentherapie und Onkologie. 2017;193(7):552–560.
   PubMed Web of Science ®Google Scholar
• Wei X, Liu HH, Tucker SL, et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy [Article]. Int J Radiat Oncol Biol Phys. 2008;70(3):707–714.
   PubMed Web of Science ®Google Scholar
• Little MP, Kleinerman RA, Stovall M, et al. Analysis of dose response for circulatory disease after radiotherapy for benign disease [Article]. Int J Radiat Oncol Biol Phys. 2012;84(5):1101–1109.
   PubMed Web of Science ®Google Scholar
• Girinsky T, M’Kacher R, Lessard N, et al. Prospective coronary heart disease screening in asymptomatic Hodgkin lymphoma patients using coronary computed tomography angiography: results and risk factor analysis [Article]. Int J Radiat Oncol Biol Phys. 2014;89(1):59–66.
   PubMed Web of Science ®Google Scholar
• Murbraech K, Smeland KB, Holte H, et al. Heart failure and asymptomatic left ventricular systolic dysfunction in lymphoma survivors treated with autologous stem-cell transplantation: A national cross-sectional study [Article]. J Clin Oncol. 2015;33(24):2683–2691.
   PubMed Web of Science ®Google Scholar
• Murbraech K, Holte E, Broch K, et al. Impaired right ventricular function in long-term lymphoma survivors [Article]. J Am Soc Echocardiography. 2016;29(6):528–536.
   PubMed Web of Science ®Google Scholar
• Maraldo MV, Giusti F, Vogelius IR, et al. Cardiovascular disease after treatment for Hodgkin’s lymphoma: an analysis of nine collaborative EORTC-LYSA trials [Article]. Lancet Haematol. 2015;2(11):e492–e502.
   PubMed Web of Science ®Google Scholar
• Van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma [Article]. J Clin Oncol. 2016;34(3):235–243.
   PubMed Web of Science ®Google Scholar
• Hahn E, Jiang H, Ng A, et al. Late cardiac toxicity after mediastinal radiation therapy for Hodgkin lymphoma: contributions of coronary artery and whole heart dose-volume variables to risk prediction [Article]. Int J Radiat Oncol Biol Phys. 2017;98(5):1116–1123.
   PubMed Web of Science ®Google Scholar
• Chow EJ, Chen Y, Kremer LC, et al. Individual prediction of heart failure among childhood cancer survivors [Article]. J Clin Oncol. 2015;33(5):394–402.
   PubMed Web of Science ®Google Scholar
• Cuculich PS, Schill MR, Kashani R, et al. Noninvasive cardiac radiation for ablation of ventricular tachycardia [Case Reports]. N Engl J Med. 2017 Dec 14;377(24):2325–2336. PubMed PMID: 29236642; PubMed Central PMCID: PMC5764179. eng.
   PubMed Web of Science ®Google Scholar
• Tong Y, Yin Y, Cheng P, et al. Quantification of variation in dose-volumeparameters for the heart, pericardium and left ventricular myocardium duringthoracic tumor radiotherapy. Journal of radiation research. 2018 Jul 1;59(4):462–468. doi:10.1093/jrr/rry026. PubMed PMID: 29659977; PubMed Central PMCID:PMC6054222
   Google Scholar
• Guzhva L, Flampouri SMendenhall NP, et al. Intrafractional Displacement ofCardiac Substructures Among Patients With Hodgkin Lymphoma or LungCancer. International Journal of Radiation Oncology Biology Physics. 2017 Oct1;99(2):S62–S62. doi:10.1016/j.ijrobp.2017.06.154. PubMed PMID:ISI:000411559106218
   Google Scholar
• Barac A, Murtagh G, Carver JR, et al. Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol. 2015 Jun 30;65(25):2739–2746. PubMed PMID: 26112199; PubMed Central PMCID: PMCPMC4484773.
   PubMed Web of Science ®Google Scholar